Medicinal Genomics

JULY 13, 2023

one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. The post 12 Things You Missed at CannMed 23 appeared first on Medicinal Genomics. Watch Dr. Russo’s Presentation Hunter Land, Ph.D,

Research and Development 52

Research and Development Cannabinoids Medicine DEA 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. Commercial Operations. Traditionally Regulated Medical Practice.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

The Blunt Truth

OCTOBER 24, 2019

The 2019 edition of the Hemp and CBD Industry Factbook released figures that show retail sales of CBD topping $1 billion this year, and predicted that number could hit $10 billion by 2024. Tourette syndrome and intractable neuropathic pain are now eligible for treatment with medical cannabis.

Hemp 58

Hemp DEA CBD Topical 58

Canna Law Blog

MARCH 7, 2023

Similarly, in spite of dozens of states enacting legislation that allows for recreational or medicinal use of cannabis, it remains federally illegal to possess, produce, and sell under the Controlled Substances Act (“CSA”) as a schedule I substance. Drug Enforcement Administration (“DEA”), the agency tasked with enforcing the CSA.

DEA 70

DEA Research and Development Programs Cannabis 70

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

Our ancestors consumed cannabis flower for recreational, medicinal, and spiritual purposes. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational Data Cannabis DEA 52